Hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome is a potentially fatal complication following hematopoietic stem cell transplantation (HSCT) and occurs in~30% of the children undergoing HSCT. 1 Two diagnostic criteria have been used for the diagnosis of VOD, the Baltimore criteria by Jones et al. 2 comprising hyperbilirubinemia of 42 mg/dL and any two of the following: weight gain of 45% from baseline, hepatomegaly or ascites. The diagnosis of VOD based on the Seattle criteria by McDonald et al. 3 can be made if any two of the following are present by day +20 after HSCT: hyperbilirubinemia (42 mg/dL), ascites or weight gain of 42% from baseline, or hepatomegaly. Prompt diagnosis and early intervention is crucial as patients with severe VOD may develop multi-organ failure, requiring intensive care and carry a high mortality of up to 84%. 4 Yet there is no consensus on grading severity of VOD. Although liver biopsy is helpful for confirming the diagnosis, in the setting of coagulopathy and thrombocytopenia, it is usually avoided. Ultrasonography has been used in the diagnosis of VOD; in the study by Lassau et al. on multivariate analysis, two ultrasound criteria (splenomegaly and ascites) and one doppler criterion (flow recorded in paraumbilical vein) were correlated with the severity of VOD (P = 0.0001). Demonstration of reversal of portal venous blood flow by ultrasonography can be helpful, but is often a late finding indicating advanced disease. 5 The Baltimore criteria are more often used in adults and appear to be more stringent than the Seattle criteria; as patients without hyperbilirubinemia are excluded. In contrast, the Seattle criteria may lead to over diagnosis, as some patients may meet the diagnostic criteria earlier in the course of the disease. Higher serum bilirubin levels have been associated with increased severity of VOD and worse outcomes. Bearman et al. 6 used total serum bilirubin level and percentage weight gain to create risk curves that would predict the likelihood of developing severe VOD. Total serum bilirubin is often used as a marker for response to treatment with defibrotide, as discussed in studies by Ho et al. 7 and Richardson et al. 8 However some patients with VOD may not have hyperbilirubinemia but still have all the other features consistent with VOD. 9, 10 In a recent study by Myers et al., 10 five patients had a bilirubin of ⩽ 2 mg/dL at the time of diagnosis of VOD and reversal of portal venous flow (PVF) by ultrasonography; two of these continued to have a bilirubin of o 2 mg/dL. 10 There have been few studies focusing specifically on anicteric VOD. The primary aim of this study is to assess the clinical course and outcomes of patients with anicteric VOD after HSCT in children.
A retrospective review of the medical charts of all patients diagnosed with VOD while undergoing HSCT from 1992 through June 2014 at Nationwide Children's Hospital, Columbus, OH, USA was performed. Both Seattle and Baltimore criteria were retrospectively applied to each patient diagnosed and treated as VOD. Patients who were diagnosed with VOD but maintained a total serum bilirubin level ⩽ 2 mg/dL during the entire course of treatment for VOD were defined as having 'Anicteric VOD'. The level of supportive care during treatment for VOD was defined as follows: 'Level 1'-general floor level management (that is, diuretics, pain control, fluid restriction, transfusion and so on), 'Level 2': paediatric intensive care unit level support for ⩽ 2 body systems (that is, mechanical ventilation for respiratory failure, vasopressors for heart failure and so on) and 'Level 3': paediatric intensive care unit level support ⩾ 3 body systems (that is, mechanical ventilation+vasopressors+dialysis and so on). Standard descriptive statistical methods were used for analysis. Statistical analysis was done using SAS 9.3 statistical software (SAS Institute, Cary, NC, USA). Categorical variables were compared between VOD groups using a Fisher's exact test. Continuous variables were compared using a nonparametric twosided Wilcoxon rank-sum test. P-values o 0.05 were considered significant. Acquisition of patient data was approved by the Institutional Review Board at Nationwide Children's Hospital.
Thirty patients were diagnosed with VOD during the study period and patient demographics and characteristics are presented in Tables 1 and 2 . One patient with undocumented bilirubin level was excluded from the study. The remaining 29 patients were included in the final analysis. Nine of 29 (31%) had anicteric VOD and 20/29 (69%) had VOD with icterus. The majority (n = 26) of the patients received myeloablative conditioning for malignant (n = 24) or non-malignant (n = 5) diseases. There was no difference in the characteristics of patients with anicteric VOD versus icteric VOD with regard to percentage weight gain, hepatomegaly, abdominal pain, demonstration of PVF reversal, duration of treatment or outcome. Ascites was seen in 5 of the 9 (55.6%) and 19 of 20 (95%) cases with anicteric and icteric VOD, respectively. The median level of supportive care was level 2 for the icteric VOD group as compared with level 1 for the anicteric group (P = 0.007).
While analysing ultrasonography results for the two groups, of the nine patients with anicteric VOD, data were missing in four (all recovered from VOD), one showed reversal of PVF and recovered, four patients had no reversal of PVF (two recovered and two died). In the icteric VOD group, 12 showed reversal of PVF (five recovered and seven died), five had no reversal of PVF (one recovered and four died) and three had missing data (two recovered and one died). Overall, six patients with no reversal of PVF died from VOD (two with anicteric VOD and four with icteric VOD).
Seven cases were diagnosed with VOD by the Seattle criteria at a median of day +15 after transplant. However, curative treatment with defibrotide was delayed by 1-11 days for lack of hyperbilirubinemia; and two of these never developed hyperbilirubinemia. Curative anticoagulation therapy was given in 1/9 (11%) cases with anicteric VOD versus 9/20 (45%) of the icteric VOD. Fourteen (14) of the 29 patients died (48%) from complications of VOD, 2 with anicteric and 12 with icteric VOD died.
Although there have been numerous studies characterizing VOD and its treatments, few studies have specifically focused on anicteric VOD. There seems to be a poor understanding and awareness of anicteric VOD as a diagnosis relative to icteric VOD. As patients with anicteric VOD do not meet the Baltimore criteria, the diagnosis of VOD and its treatment may be delayed if only the Baltimore criteria are followed. It is well known that delay in the initiation of supportive care and curative treatment may result in worse outcomes. 11 Corbacioglu et al. 12 showed that response to treatment with defibrotide may be lower if there is a delay in starting treatment by more than 2 days after diagnosis of VOD (CR rate 39% if ⩽ 2 days versus 25% if 42 days; P = 0.005). Nearly one third of the patients in our study had anicteric VOD. None would have met the Baltimore criteria for diagnosis of VOD and may have not been treated if the Seattle criteria were not applicable.
We also found that lack of hyperbilirubinemia led to a delay in diagnosis of VOD, even if hyperbilirubinemia is not a mandatory Seattle criterion. It is difficult to say if the delay in starting treatment had any impact on the outcome in our study. Children undergoing HSCT should be very closely monitored for weight gain, ascites, hepatomegaly abdominal pain and increased requirement for platelets. The Seattle criteria should be applied to patients at risk of developing VOD and one should not wait for hyperbilirubinemia to develop before diagnosing VOD. Early initiation of treatment is known to have better outcome in patients with VOD.
Several studies have suggested that bilirubin levels have a direct correlation with the severity of the disease and they have been used to classify the severity of VOD. 6, 13 However, patients with anicteric VOD should not be overlooked as having insignificant disease. Although patients with anicteric VOD typically had better outcomes than those with hyperbilirubinemia, our study shows that there can be significant morbidity and even mortality associated with anicteric VOD.
Reversal of PVF may not be present in all cases with VOD, as 6/29 (21%) analysed patients had no reversal of PVF and died (two with anicteric and four with icteric VOD), suggesting that VOD cannot be ruled out in the absence of reversal of PVF. Our results are similar to the study by Myers et al. 10 who reported five patients with anicteric VOD at diagnosis, two of those remained anicteric and one of these two died. 10 Our study reconfirms the importance of not overlooking a diagnosis of VOD simply due to lack of hyperbilirubinemia. Anicteric VOD is common in children after HSCT and carries a significant morbidity and even mortality. All patients should be closely monitored for symptoms and signs of VOD and treatment should be initiated as soon as possible. There is a need to redefine the VOD diagnostic criteria and treatment guidelines based on severity. Abbreviations: BM = bone marrow; MA = myeloablative; PBSC = peripheral blood stem cell; RIC = reduced intensity conditioning; TBI = total body irradiation; UCB = umbilical cord blood; VOD = veno-occlusive disease.
